Sarepta sinks after eteplirsen panel

Sarepta Therapeutics Inc. (NASDAQ:SRPT) sank $3.93 (26%) to $11.02 on Tuesday after an FDA advisory committee voted Monday that the company did not provide substantial evidence that eteplirsen ( AVI-4...